Kotaro Maeda

Dr. Kotaro Maeda


Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 July 2020 in BMC Cancer
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsuoka
Hiroshi Matsuoka
THTakahiro Hayashi
Takahiro Hayashi
KTKaren Takigami
Karen Takigami
Kazuyoshi ImaizumiKazuyoshi Imaizumi
Kazuyoshi Imaizumi
RSRyoichi Shiroki
Ryoichi Shiroki
IUIchiro Uyama
Ichiro Uyama
Background: Immune checkpoint inhibitors (ICIs) targeting programmed cell death protein 1 (PD-1) are used for the treatment of various cancer types. However, immune-related adverse events (irAEs) occur in patients treated with ICIs. Several small-scale studies have reported the onset of irAEs and therapeutic effects of ICIs. Here we report a large-scale retrospective study covering a wide range of cancers. We evaluated irAEs and the therapeutic effects of ICIs and determined whether irAEs could be predicted. Methods: This study included patients treated with the anti-PD-1 antibodies nivolumab or pembrolizumab at Fujita Health University Hospital between December 2015 and March 2019. We retrospectively reviewed the electronic medical records for age, cancer type, pre-treatment blood test data, presence or absence of irAE onset, type and severity of irAEs, outcome of irAE treatment, response rate, progression-free survival and overall survival. Results: Two hundred-eighty patients received ICIs. The overall incidence of irAEs was 41.1% (115 patients), and the incidence of severe irAEs of grade 3 and higher was 2.8% (eight patients). The most common irAEs were skin disorders, thyroid disorders and interstitial pneumonitis. Patients with irAEs were significantly older than those without irAEs (69.7 versus 66.0 years, P = 0.02). The objective response rate (ORR) in patients with irAEs was 30.4%, which was significantly higher than in patients without irAEs (12.7%; P < 0.01). Both the median overall and progression-free survival were significantly longer in patients with irAEs (P < 0.01, p < 0.01). Based on the blood test data obtained before ICI therapy, hypothyroidism, thyroid-stimulating hormone levels and thyroglobulin antibody levels were associated with the onset of irAEs. In many patients with irAEs of Common Terminology Criteria for Adverse Events Grade 3 or higher, re-administration of ICIs was difficult, and their outcomes were poor. In contrast, many patients with irAEs of a lower grade were able to resume ICI therapy. Conclusion: Although the onset of irAEs was difficult to be predicted based on pre-treatment tests. It appeared that the continuation of ICI therapy, along with early detection and adequate control of irAEs, might contribute to the improved prognosis of patients.

1 April 2003 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
KMKotaro Maeda
Kotaro Maeda
MMM. Maruta
M. Maruta
TUT. Utsumi
T. Utsumi
HSH. Sato
H. Sato
KTK. Toyama
K. Toyama
HMH. Matsuoka
H. Matsuoka

1 October 2004 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
KMKotaro Maeda
Kotaro Maeda
MMMorito Maruta
Morito Maruta
THTsunekazu Hanai
Tsunekazu Hanai
HSHarunobu Sato
Harunobu Sato
YHYoshimune Horibe
Yoshimune Horibe
Rectal stump washout has been recommended to prevent implantation of exfoliated malignant cells in the anastomosis after anterior resection for rectal cancer. The aim of this study was to investigate its efficacy, particularly the extent to which the volume of irrigation fluid might influence the efficacy of tumor cell elimination and whether tumor characteristics might influence the result. The study comprised 30 consecutive patients operated on by anterior resection for rectal cancer. After cross-clamping the rectum below the tumor, a washout sample was collected for examination after every incremental 500 ml of saline irrigation up to 2 liters. The presence of shed cancer cells was correlated with the washout volume and tumor characteristics. Cancer cells were found in 29 of 30 patients (97 percent) in the first sample of irrigation fluid and decreased gradually in frequency and number with increasing irrigation volumes. No cancer cells were demonstrated after 1.5 liters of irrigation in patients with tumor below the peritoneal reflection, whereas cancer cells were still present in one-fourth of the patients with tumor located above the peritoneal reflection. Finally, only a small number of cancer cells was confirmed in one patient after 2 liters of irrigation. The irrigation volume determined the efficacy of rectal washout. With our method, 1 1/2 liters of saline irrigation appears to clear contents from cancer cells in patients with tumors below the peritoneal reflection whereas at least 2 liters is recommended for patients with tumor above the peritoneal reflection.

1 March 2004 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
KMKotaro Maeda
Kotaro Maeda
MMM. Maruta
M. Maruta
TUT. Utsumi
T. Utsumi
HSH. Sato
H. Sato
HAH. Aoyama
H. Aoyama
LHL. Hultén
L. Hultén

1 July 2003 in Techniques in Coloproctology
Verified
Journal Article
Closed access
PDF file
KMKotaro Maeda
Kotaro Maeda
MMM. Maruta
M. Maruta
TUT. Utsumi
T. Utsumi
HSH. Sato
H. Sato
KMK. Masumori
K. Masumori
HAH. Aoyama
H. Aoyama

15 February 2019 in World Journal of Surgical Oncology
Verified
Journal Article
Open access
PDF file
HMHiroshi Matsuoka
Hiroshi Matsuoka
ZMZenichi Morise
Zenichi Morise
CTChihiro Tanaka
Chihiro Tanaka
THTakahiro Hayashi
Takahiro Hayashi
YIYoshiaki Ikeda
Yoshiaki Ikeda
IUIchiro Uyama
Ichiro Uyama
Although hepatectomy for metastatic colorectal cancer (mCRC) prolongs survival in up to 40% of people, recurrence rates approach 70%. We used a multidisciplinary approach to treat recurrent liver metastases, including chemotherapy, surgery, and palliative care. On the other hand, development of chemotherapeutic agents is remarkable and improves long-term survival. However, whether chemotherapy and repeat hepatectomy combination therapy improve survival or not is still unclear. The aim of this study was to analyze the outcomes of repeat hepatectomy with systemic chemotherapy for mCRC. Following Institutional Review Board approval, we reviewed the records of all patients who underwent hepatectomy for mCRC between 1974 and 2015 at Fujita Health University Hospital. We used the Kaplan–Meier method to estimate overall survival from the first and last hepatectomy in multi hepatectomy cases after 2005 and compared outcomes between groups using the log-rank test. A total of 426 liver resections were performed for mCRC; of these, 236 cases were performed after 2005 (late group). In 118 (50%) cases, the site of recurrence was the liver, 59 (50%) underwent repeat hepatectomy, and 14 cases had ≥ 2 repeat hepatectomies. Overall survival (OS) before and after 2005 was 42.2 and 64.1 months, respectively, with the late group having better OS compared to the early (1974–2004) group. OS for single hepatectomy cases was 83.2 months, for two hepatectomies was 42.9 months, and for three hepatectomies was 35.3 months. In total, 59 patients did not undergo surgery after recurrence with an OS of 28.7 months. Mortality of the second and third repeat hepatectomy was 1.7% and 15.3%, respectively. Repeat hepatectomy with systemic chemotherapy for mCRC is feasible and might achieve improved survival in carefully selected patients.